GYRO
Gyrodyne, LLC9.17
+0.00+0%
Dec 15, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
20.17MP/E (TTM)
43.68Basic EPS (TTM)
0.21Dividend Yield
0%Recent Filings
8-K
8-K
Gyrodyne settles board dispute
Gyrodyne locked in a deal with Star Equity on October 16, 2025, pulling their board nomination threat in exchange for slashing the board from five to four directors and capping chairman fees at $65,000. Star Equity commits to backing board picks until 2026—or 2027 if key directors re-up—while standstill rules curb proxy fights. A separate pact with Leap Tide and directors seals similar voting support through 2028. Board shrinks fast. This settles activist noise, steadying governance amid property sale pushes, though litigation risks linger.
10-Q
Q2 FY2025 results
Gyrodyne's net assets in liquidation climbed to $32.6M as of June 30, 2025, up 6.6% from $30.6M at year-end 2024, driven by a $4.5M boost in real estate values from ongoing entitlement pursuits, though offset by $2.5M in remeasured costs for a timeline extension to 2027. Estimated distributions per share rose to $14.83 from $13.91, based on 2,199,308 shares outstanding. Cash stood at $5.5M, supporting operations amid $11.0M in loans maturing through 2028 at rates around 3.75%-3.85%, while a July 2025 deal to sell 49 acres of Flowerfield for up to $28.7M awaits subdivision and site approvals. Leasing added $105K in annual revenue from new deals. Yet regulatory appeals could drag timelines further.
8-K
Gyrodyne inks Flowerfield land deal
Gyrodyne's subsidiary signed a purchase and sale agreement on July 30, 2025, to sell a 49-acre vacant land parcel in its Flowerfield complex to B2K Smithtown LLC for $24 million to $28.74 million, contingent on approvals for market-rate units. The deal extends the company's liquidation timeline to December 31, 2027, while boosting estimated NAV to $32.6 million or $14.83 per share as of June 30, 2025—a 6% rise. Approvals hinge on regulatory hurdles; delays could drag closure to 2028.
10-Q
Q1 FY2025 results
Gyrodyne's net assets in liquidation climbed $216,077 quarter-over-quarter to $30.81 million as of March 31, 2025, lifting estimated distributions to $14.01 per share from $13.91 (derived). This uptick stemmed from $181,000 in stronger rental receipts and trims in rental expenses by $16,000 alongside general administrative savings of $67,000, though offset by $50,000 in added land development fees. Cash dipped slightly to $5.79 million, with total loans payable steady at $11.09 million across fixed-rate facilities maturing through 2029. Entitlement pursuits advanced, with Flowerfield subdivision eyed for Q3 2025 approval and Cortlandt Manor in mid-2026, backed by JLL's marketing push. Yet regulatory appeals drag on timelines. Litigation lingers as a key hurdle.
AOXY
Advanced Oxygen Technologies, I
0.08+0.00
BALDF
FASTIGHETS AB BALDER
6.76+0.00
BRST
Broad Street Realty Inc.
0.01+0.00
CPTP
Capital Properties, Inc.
12.10+0.10
DEA
Easterly Government Properties,
22.26-0.16
EUDA
Euda Health Holdings Limited
2.40+0.14
MAYS
J. W. Mays, Inc.
38.25+0.00
NYC
American Strategic Investment C
7.85+0.29
SLG
SL Green Realty Corp
45.75+0.16
ZDPY
Zoned Properties, Inc.
0.48+0.00